Bank Of America Corp Athira Pharma, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 228,655 shares of ATHA stock, worth $150,912. This represents 0.0% of its overall portfolio holdings.

Number of Shares

228,655

Previous 228,402 0.11%

Holding current value

$150,912

Previous $625,000 3.2%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.92 - $2.71 $485 - $685	253 Added 0.11%	228,655 $605,000
Q1 2024 May 15, 2024	BUY	$2.24 - $4.15 $402,541 - $745,779	179,706 Added 369.04%	228,402 $625,000
Q4 2023 Feb 14, 2024	SELL	$1.39 - $2.46 $585,210 - $1.04 Million	-421,015 Reduced 89.63%	48,696 $118,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $9,270 - $14,101	-3,928 Reduced 0.83%	469,711 $1.39 Million
Q1 2023 May 12, 2023	BUY	$2.26 - $4.22 $10,111 - $18,880	4,474 Added 0.95%	473,639 $1.18 Million
Q4 2022 Feb 10, 2023	SELL	$2.76 - $3.71 $55,445 - $74,530	-20,089 Reduced 4.11%	469,165 $1.49 Million
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $178,038 - $240,625	60,764 Added 14.18%	489,254 $1.45 Million
Q2 2022 Aug 12, 2022	BUY	$2.74 - $13.43 $191,109 - $936,715	69,748 Added 19.44%	428,490 $1.31 Million
Q1 2022 May 16, 2022	BUY	$8.96 - $13.51 $1.08 Million - $1.63 Million	120,876 Added 50.82%	358,742 $4.84 Million
Q4 2021 Feb 08, 2022	BUY	$9.17 - $16.39 $225,902 - $403,767	24,635 Added 11.55%	237,866 $3.1 Million
Q3 2021 Nov 15, 2021	BUY	$9.15 - $11.09 $1.8 Million - $2.18 Million	196,482 Added 1173.1%	213,231 $2 Million
Q2 2021 Sep 13, 2021	BUY	$10.24 - $20.87 $171,509 - $349,551	16,749 New	16,749 $172,000

Others Institutions Holding ATHA

# of Institutions

Shares Held

22.2M

Call Options Held

73.4K

Put Options Held

97.8K

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $25M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Athira Pharma, Inc. Transaction History